This segment focuses on the research, development, and clinical trials of novel therapies for metabolic and endocrine disorders. Key activities include the development of VK2809 for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, and VK0214 for X-linked adrenoleukodystrophy. Research and development efforts involve small molecule drug discovery, preclinical studies, and clinical trials across various phases. The segment utilizes advanced technologies and methodologies in drug development, including receptor-subtype selective agonists. The primary therapeutic areas are metabolic and endocrine disorders, with the goal of improving patient outcomes and addressing unmet medical needs. Market positioning is based on developing first-in-class or best-in-class therapies. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a core component, and the company has partnerships with CordenPharma for manufacturing and other collaborations for research.

This segment is dedicated to the development of novel therapies for obesity, with a primary focus on the GLP-1/GIP agonist VK2735. Research and development activities include preclinical studies, formulation development, and clinical trials, including a Phase 3 obesity clinical program. The segment leverages advanced technologies in peptide and small molecule drug development. The therapeutic area is obesity, with the aim of providing effective and safe treatments for weight management. Patient impact is focused on improving metabolic health and reducing the risks associated with obesity. Market positioning is based on the potential of VK2735 to offer a differentiated approach to obesity treatment. Future opportunities include securing regulatory approvals and expanding the clinical program. Regulatory and clinical aspects are critical, with ongoing Phase 2 and Phase 3 trials. The company has a manufacturing agreement with CordenPharma to support the commercialization of VK2735.